Adding Nivolumab to Standard First-Line Therapy Feasible in Advanced Head and Neck Cancer
An early phase trial found that it is feasible to combine nivolumab immunotherapy with radiation therapy and chemotherapy in patients with newly diagnosed local-regionally advanced head and neck cancers.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Dave Levitan Tags: Head & Neck Cancer News Radiation Oncology Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Head and Neck Cancer | Immunotherapy | Radiation Therapy